PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?
Looking for a particular PreludeDx employee's phone or email?
PreludeDx Questions
The PreludeDx annual revenue was $4 million in 2026.
Dan Forche is the President and CEO of PreludeDx.
61 people are employed at PreludeDx.
PreludeDx is based in Laguna Hills, California.
The NAICS codes for PreludeDx are [6215, 621, 62151, 62].
The SIC codes for PreludeDx are [807, 80].
Top PreludeDx Employees
-
Dan Forche
President and CEO at PreludeDx
San Clemente, CA, US35+ -
Andy Wade
Chief Financial Officer at PreludeDx
Irvine, CA, US35+ -
Joseph Nollar
Vice President of Technology at PreludeDx
Laguna Hills, CA, US25 -
Troy Bremer
Chief Scientific Officer at PreludeDx
Laguna Hills, CA, US45 -
David Peterson
VP, Revenue Cycle at PreludeDx
San Diego, CA, US15+ -
Leona Hamrick
Vice President, Global Medical Affairs (Breast Cancer) at PreludeDx
Florida, United States22 -
Pat Whitworth
Chief Medical Officer at PreludeDx
Nashville, TN, US13
Related Companies
